Ifosfamide, mitomycin and radiotherapy in non-small-cell lung cancer
Tóm tắt
Ifosfamide and mitomycin C are two of the more active single agents in non-small-cell lung cancer (NSCLC). This study evaluates these drugs in combination followed by radiotherapy. A total of 33 ambulatory patients with inoperable NSCLC were treated with 5 g/m2 ifosfamide as a 24-h infusion, with the concurrent administration of sodium 2-mercaptoethane sulphonate (mesna; 160% of the ifosfamide dose) and 6 mg/m2 mitomycin C given as an i.v. bolus injection on the 2nd day. The median age of the patients was 61 years. In all, 20 patients had limited disease and 13, extensive disease. A total of 30 were assessable for response to chemotherapy, 8 of whom achieved a partial response (PR) and 5, a complete response (CR) (2 were verified bronchoscopically). The overall response rate was thus 43%. All but one response (a PR) were in patients with limited disease (LD). A total of 21 patients, including 13 responders, received thoracic irradiation (30 Gy in 8 fractions over 10 days) following chemotherapy. One PR was converted to a radiological CR. In all, 17 (55%) of the patients were alive at 1 year. All patients suffered chemotherapy-induced alopecia (WHO grade 3), but there were no treatment modifications due to myelosuppression, haemorrhagic cystitis or other toxicity. WHO grade 3 nausea and vomiting were seen in all patients. There was one treatment-related death. Combination therapy using ifosfamide and mitomycin C has useful activity in NSCLC.
Tài liệu tham khảo
Bakowski MT, Crouch JC (1983) Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future. Cancer Treat Rev 10: 159
Costanzi JJ, Morgan LR, Hokanson J (1982) Ifosfamide in the treatment of extensive non-oat cell carcinoma of the lung. Semin Oncol 9: 61
Cullen MH, Joshi R, Chetiyawardana A, Woodroffe CM (1988) Mitomycin, ifosfamide and cisplatin in non-small cell lung cancer: treatment good enough to compare. Br J Cancer 58: 359
Dejager R, Longeval E, Klastersky J (1980) High dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II trial of the EORTC lung cancer working party (Belgium). Cancer Treat Rep 64 (12): 1341
Harrison EF, Hawke JE, Costanzi JJ, Morgan LR, Plotkin D, Tucker WG, Worrall PM (1982) Single dose ifosfamide; efficacy studies in non-small cell lung cancer. Semin Oncol 9: 56
Klastersky J, Longeval E, Nicaise C (1982) Etoposide and cisplatinum in non-small cell bronchogenic carcinoma. Cancer Treat Rev 9: 133
Kris M, Cohen E, Gralla R (1985) An analysis of 134 phase II trials in non-small cell lung cancer (NSCLC) (Abstract). Proceedings of the 4th World Conference on Lung Cancer, Toronto, August 25–30, 1985, p 39
Main J, Clarke RA, Hutcheon A (1986) Vindesine and mitomycin C in inoperable non-small cell lung cancer. Eur J Cancer Clin Oncol 22 (8): 983
Morgan LR, Posey LE, Rainey J, Bickers J, Ryan D, Vial R, Hull EW (1981) Ifosfamide. A weekly dose fractionated schedule in bronchogenic carcinoma. Cancer Treat Rep 65 (7–8): 693
Ruckdeschel JC, Mehta CR, Salazar OM, Cohen M, Vogl S, Koons LS, Lerner H (1981) Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST-2575. Generation II. Cancer Treat Rep 65 (11–12): 965
Samson MK, Comis RL, Baker LH, Ginsberg S, Fraik RJ, Crooke ST (1978) Mitomycin C in advanced adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 62 (1): 163
Whittington RM, Close HP (1970) Clinical experience with mitomycin C (NSC-26980). Cancer Chemother Rep Part 1 54 (3): 195